10-K: Quoin Pharma's 2025 10-K: NS Drug Progress Amidst Financial Strain

Quoin Pharmaceuticals reports significant clinical progress for its lead Netherton Syndrome drug QRX003, including positive Phase 2 data and FDA openness to pivotal study design, despite ongoing substantial net losses and a going concern warning.

Summary

• Quoin Pharmaceuticals is a late-stage clinical specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases.
• The lead product, QRX003, is under clinical development for Netherton Syndrome (NS) and is entering pivotal registrational clinical testing under an open Investigational New Drug (IND) application with the FDA.
• Six clinical sites in the U.S. and international sites in the UK, Spain, France, and the Netherlands are opening for QRX003 in NS.
• QRX003 is currently being tested in seven pediatric NS patients in investigator-initiated studies across Ireland, Austria, the Netherlands, and New Zealand.
• QRX003 is also being developed as a potential treatment for Peeling Skin Syndrome, with the first subject treated in New Zealand and plans to expand to an additional five pediatric subjects.
• The company discontinued the development of QRX007 for NS in July 2025.
• Quoin holds an option for a global license to QRX008 for scleroderma from Queensland University of Technology (QUT).
• A Research Agreement with University College Cork (UCC) is in place for the development of novel topical rapamycin (sirolimus) formulations (QRX009) for various rare diseases, including microcystic lymphatic malformations, venous malformations, and angiofibromas.
• Target loading concentrations of 4% w/w for a proprietary topical formulation and 5% w/w for a dermal patch system have been achieved for QRX009.
• The company has established 9 commercial partnerships for QRX003 covering 61 countries outside its core commercial territories of the U.S., Western Europe, and Japan.
• Quoin Pharmaceuticals reported an accumulated deficit of approximately $71.0 million at December 31, 2025.
• Cash and cash equivalents totaled $3.8 million and investments were $14.9 million as of December 31, 2025.
• The net loss for the year ended December 31, 2025, was $15.8 million, an increase from $8.96 million in 2024.
• Research and development expenses increased by 172% to $9.8 million in 2025 from $3.6 million in 2024.
• General and administrative expenses increased by 9.5% to $6.49 million in 2025 from $5.93 million in 2024.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least one year.
• The October 2025 Private Placement generated approximately $15 million in net proceeds, with a potential for up to $88 million in additional gross proceeds from warrant exercises.
• The FDA indicated that a single Phase 3 study may be sufficient to support marketing approval for QRX003 in NS and expressed openness to an alternative study design without a traditional upfront vehicle or placebo control.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While clinical progress and regulatory designations for QRX003 are highly positive and crucial for a biotech, the significant increase in net loss and the explicit 'going concern' warning highlight severe financial instability and a high dependency on future capital raises.

Positives

• QRX003 for Netherton Syndrome (NS) is entering pivotal registrational clinical testing under an open IND with the FDA.
• The FDA indicated that a single Phase 3 study may be sufficient for QRX003 in NS and expressed openness to an alternative study design without a traditional upfront vehicle or placebo control, potentially accelerating the approval pathway.
• QRX003 received Orphan Drug Designation from the European Medicines Agency (EMA), which could result in 10 years of market exclusivity in Europe upon approval.
• The FDA granted Rare Pediatric Disease Designation to QRX003 for NS, enabling potential Priority Review Voucher eligibility upon marketing approval.
• The FDA also granted Orphan Drug Designation and Fast Track Designation to QRX003 for NS, which can expedite development and review.
• An application for Breakthrough Medicine Designation for QRX003 was filed with the Saudi Food and Drug Authority (SFDA), aiming for accelerated regulatory review and earlier patient access in Saudi Arabia.
• An application for Orphan Drug Designation for QRX003 for NS was submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW), which could provide R&D subsidies, tax credits, fee reductions, priority review, and 10 years of market exclusivity if approved.
• Initial clinical data from Study CL-QRX003-002 Part A showed two of seven NS subjects achieved a one-grade improvement in IGA and five of seven subjects had a two-grade improvement in WI-NRS (p-value of 0.001) with low potency cosmetic grade DPHP.
• Single subject data from Study CL-QRX003-002 Part B demonstrated significant improvements in NS symptoms after 12 weeks of twice-daily QRX003 treatment: IGA improved from 3 (moderate) to 1 (almost clear), WI-NRS from 7 to 2, and M-IASI from 18 to 3.
• An investigator-initiated study of QRX003 in pediatric NS patients showed one subject's skin adjudicated as clear (IGA 4 to 0) and pruritus rated as no itch (5 to 0) after 12 months, with zero nightly sleep disturbance and no need for other medications, and no treatment-related adverse events.
• The first pediatric Peeling Skin Syndrome patient treated with QRX003 showed improvement across all evaluated endpoints (M-IASI 36 to 12, IGA 4 to 2, CDQLI 19 to 11) after 12 weeks, with continued improvement over one year and significantly diminished pruritus.
• Target loading concentrations for two topical rapamycin delivery technologies (4% w/w proprietary topical formulation, 5% w/w dermal patch system) for QRX009 have been successfully achieved.
• The company has established 9 commercial partnerships for QRX003, covering 61 countries outside its core commercial territories, indicating broad market access potential.
• The October 2025 Private Placement raised approximately $15 million in net proceeds, strengthening the company's financial position.
• There is a potential for up to $88 million in additional gross proceeds if the October 2025 Ordinary Warrants are exercised in full for cash.
• Cash and investments increased from $14.06 million at December 31, 2024, to $18.745 million at December 31, 2025.

Negatives

• The company has incurred significant losses since its inception, with an accumulated deficit of approximately $71.0 million at December 31, 2025.
• The net loss for the year ended December 31, 2025, increased significantly to $15.8 million from $8.96 million in 2024.
• Research and development expenses increased by 172% to $9.8 million in 2025, indicating a high and increasing cash burn rate.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for a period of at least one year.
• The company has never generated any revenue from product sales or any other sources since inception and may never be profitable.
• Additional capital is required to fund operations, and there is no assurance that such funding will be available on acceptable terms or at all.
• Restrictive covenants from the October 2025 private placement (prohibiting variable rate financings until April 12, 2026, and equity financings below the unit purchase price until June 2, 2026) may hinder future financing efforts.
• One pediatric NS subject's symptoms returned to, or were worse than, baseline levels four weeks after QRX003 treatment discontinuation, highlighting the chronic nature of the disease and the need for continuous treatment.
• The development of QRX007 for Netherton Syndrome was discontinued in July 2025.
• One patent expired in March 2024, and another in July 2025, potentially reducing intellectual property protection.
• The decrease in interest income in 2025 was due to lower average aggregate cash and investment balances and a decrease in interest rates.

Risks

• The company has a limited operating history and faces inherent difficulties, expenses, and delays common to small developing companies.
• Additional capital must be raised to fund operations to continue as a going concern.
• The company has a history of losses and may be unable to fund its business from operations, potentially requiring additional capital on unfavorable terms or not at all.
• There is a lack of revenue and potential inability to achieve profitability.
• Uncertainties exist regarding cash flows and the ability to meet working capital needs.
• The terms of the October 2025 private placement may make it difficult to procure additional financing.
• There is no assurance of obtaining regulatory approvals for product candidates.
• The ability to generate favorable pre-clinical and clinical trial results is uncertain.
• The company may not be successful in identifying or developing potential product candidates.
• Clinical trials may fail to demonstrate safety and efficacy, leading to additional costs or delays.
• Product candidates may cause undesirable side effects or have other safety issues, delaying or preventing regulatory approval.
• The timing of revenue from future product sales cannot be predicted due to uncertainties in regulatory approval.
• Even with regulatory approval, extensive regulatory requirements and future development/regulatory challenges will persist.
• The company may not be able to maintain orphan drug designation or obtain orphan drug exclusivity for its product candidates.
• Rare Pediatric Disease designation does not guarantee a priority review voucher or faster development/regulatory review.
• Financial and human resources may be used to pursue less profitable or less successful research programs.
• Significant competition is expected in the marketplace for product candidates, if approved.
• Operating results will suffer if the company fails to compete effectively against other biotechnology and pharmaceutical companies.
• Commercial success depends on acceptance by the medical community, including physicians, patients, and healthcare payors.
• Inability to establish sales and marketing capabilities or enter into third-party agreements may prevent revenue generation.
• International operations carry additional risks, including differing regulatory requirements, reimbursement regimes, and intellectual property protection.
• Coverage and adequate reimbursement may not be available for product candidates, if approved, making profitable sales difficult.
• Reliance on third parties for compound formulation, research, and pre-clinical studies may lead to unsatisfactory performance or missed deadlines.
• Reliance on third-party manufacturers for clinical and commercial supplies entails risks, including compliance with cGMP regulations.
• Limited sources of supply for drug substance may cause delays in development and commercialization.
• Manufacturing issues may arise, increasing costs or delaying commercialization.
• Reliance on third parties to conduct, supervise, and monitor clinical trials may harm the business if they perform unsatisfactorily.
• Inability to obtain or protect intellectual property rights may hinder effective competition.
• Third-party claims of intellectual property infringement may prevent or delay development and commercialization efforts.
• Failure to obtain licenses or comply with obligations in intellectual property licensing agreements could result in loss of critical rights.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Employees, consultants, or independent contractors may wrongfully use or disclose confidential information of third parties.
• Pausing or termination of government grants could significantly affect operations and prospects.
• Inadequate funding, government shutdowns, or policy changes affecting regulatory agencies (FDA, SEC) could negatively impact the business.
• Future success depends on the ability to attract and retain key executives and qualified personnel.
• Expansion of the organization may lead to difficulties in managing growth and disrupt operations.
• Employee misconduct or other improper activities, including noncompliance with regulatory standards and insider trading, pose risks.
• Future relationships with customers and third-party payors may be subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with potential for criminal sanctions or civil penalties for non-compliance.
• Changes to current regulations and future legislation (e.g., healthcare reform, drug pricing initiatives) could impact operations and commercial success.
• Potential product liability claims could result in substantial liability and costs.
• Cybersecurity risks and failures to maintain IT system confidentiality, integrity, and availability could damage reputation or lead to costs, fines, or lawsuits.
• Health epidemics and pandemics may adversely affect business, prospects, financial condition, and operating results.
• Business interruptions (e.g., natural disasters) could delay product development.
• Shareholders may face difficulties enforcing U.S. judgments or asserting U.S. securities laws claims in Israel.
• Rights and responsibilities of shareholders are governed by Israeli law, which may differ from U.S. corporations.
• Provisions of Israeli law may delay, prevent, or impede mergers or acquisitions.
• There is no assurance that a sustained market for the company's securities will exist, making it difficult for shareholders to sell.
• Complying with laws and regulations affecting public companies incurs costs and demands on management.
• Failure to achieve and maintain effective internal controls could materially adversely affect the business and stock price.
• Failure to meet Nasdaq continued listing requirements could result in delisting of ADSs.
• The market price for ADSs may be volatile.
• The company may be at risk of securities class action litigation.
• Substantial future sales or perceived potential sales of ADSs could cause the price to decline.
• Shareholders may experience substantial dilution from future equity security issuances.
• The company has not paid and does not intend to pay dividends, so investors may not benefit unless securities appreciate in value.
• ADS holders may not receive the same distributions or dividends as ordinary shareholders and may be subject to transfer limitations.

Future Outlook

Quoin Pharmaceuticals plans to complete late-stage clinical testing of QRX003 for Netherton Syndrome and, if successful, submit for marketing approval in the U.S., Europe, Japan, and other territories. The company intends to establish its own sales infrastructure in core markets and work with partners elsewhere. Development of QRX003 for Peeling Skin Syndrome and related genetic skin diseases will continue, with plans to expand the current study. Clinical testing for QRX009 (topical rapamycin formulations) is targeted to commence in the second half of 2026, following a pre-IND meeting request to the FDA and a pharmacokinetic study in Q2 2026. The company expects to incur significant expenses and increasing operating losses, necessitating additional capital raises to fund future operations and achieve commercial profitability.

Management Comments

• Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly for those diseases where no approved treatment currently exists.
• We believe, to date we are the only company that is actively dosing subjects in multiple NS clinical studies under an open IND with the FDA.
• We expect to continue our research and development efforts by conducting the remaining studies necessary for the development and approval of QRX003.
• Management has concluded that there is substantial doubt about our ability to continue as a going concern for a period of at least one year from the issuance of the audited consolidated financial statements.

Industry Context

StockSavvy.ai notes that Quoin Pharmaceuticals operates in the highly competitive and capital-intensive rare and orphan disease pharmaceutical sector. The company's focus on Netherton Syndrome, a condition with no approved treatments, positions it in a high-need market. The regulatory designations (Orphan Drug, Rare Pediatric Disease, Fast Track) for QRX003 are critical in this space, offering potential market exclusivity and expedited review, which are significant advantages against competitors like LifeMax Laboratories, Sixera Pharmaceuticals, ResVita Bio, BioCryst, and Azitra Inc., especially since only Azitra and BioCryst are also actively dosing NS patients in clinical studies under an open IND. The reliance on third-party manufacturers and CROs is a common industry practice for smaller biotechs, but also introduces supply chain and quality control risks. The ongoing need for capital raises and the 'going concern' warning are typical challenges for clinical-stage pharmaceutical companies without commercialized products.

Comparison to Industry Standards

• The company's strategy to self-commercialize in the U.S., Europe, and Japan, while partnering in other regions, aligns with common practices for specialty pharmaceutical companies targeting niche markets, allowing for focused sales efforts due to the concentrated nature of rare disease treatment by a small number of specialists.
• The receipt of Orphan Drug Designation (EMA and FDA), Rare Pediatric Disease Designation (FDA), and Fast Track Designation (FDA) for QRX003 for Netherton Syndrome are standard and highly sought-after regulatory incentives in the rare disease space, comparable to designations received by other companies developing treatments for similar unmet medical needs. For example, companies like Sanofi (for Fabry disease) or Alexion (for atypical HUS) have leveraged such designations to secure market exclusivity and accelerate development.
• The clinical trial results for QRX003 in NS, particularly the significant improvements in IGA and WI-NRS in a single pediatric subject (IGA 4 to 0, Pruritus 5 to 0), are promising for a rare disease, where smaller patient populations often lead to single pivotal studies being acceptable, as indicated by the FDA's openness to baseline-controlled pivotal studies. This is a common pathway for orphan drugs, contrasting with the larger, multi-study requirements for more prevalent conditions.
• The company's accumulated deficit of $71.0 million and the 'going concern' warning are typical for a late-stage clinical pharmaceutical company that has not yet commercialized a product, similar to many pre-revenue biotechs that rely heavily on capital raises to fund extensive R&D.
• The increase in R&D expenses by 172% to $9.8 million in 2025 reflects the typical ramp-up in costs as product candidates advance into later-stage clinical trials, which is a standard progression in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• Not aware of any pending or threatened material legal or administrative proceedings against the company.

Related Party Transactions

• Repaid $300,000 of indebtedness to Dr. Michael Myers (CEO) and $300,000 to Ms. Denise Carter (COO) during the year ended December 31, 2025.
• As of December 31, 2025, approximately $1,359,000 of indebtedness was outstanding to Dr. Myers and $965,000 to Ms. Carter.
• The estimated liability to the remaining three 2020 Noteholders, including directors Dennis Langer and James Culverwell, was $1,146,000 as of December 31, 2025 and 2024.
• Dr. Myers, Ms. Carter, Mr. Dunn, and Mr. Culverwell purchased an aggregate of 38,095 ADSs and accompanying December 2024 Warrants (76,190 ADSs) for approximately $600,000 in the December 2024 Offering.
• Director Dennis Langer participated in the October 2025 Private Placement, purchasing 15,152 ADSs and accompanying October 2025 Ordinary Warrants for approximately $128,641.
• Sally Lawlor (Chief Financial Officer) is the niece of Dr. Michael Myers (Chairman and Chief Executive Officer).

Stakeholder Impact

• **Shareholders:** Face potential for significant dilution from future equity raises and a risk of losing investment due to the 'going concern' uncertainty. However, there is potential for substantial appreciation if QRX003 is successfully commercialized. ADS holders have limited voting rights and no anticipated dividends.
• **Employees:** The company's success depends on its ability to attract and retain key executives and qualified personnel. Employees are subject to the risk of misconduct and benefit from equity-based compensation plans.
• **Future Patients/Customers:** Stand to benefit from potential new treatments for rare and orphan diseases like Netherton Syndrome and Peeling Skin Syndrome, but face the risk of product candidates not receiving regulatory approval or having undesirable side effects.
• **Creditors:** Exposed to the risk of the company being unable to satisfy existing and foreseeable obligations due to the 'going concern' uncertainty and ongoing losses.
• **Suppliers/Partners:** The company's reliance on third-party manufacturers and Contract Research Organizations (CROs) means these stakeholders face risks of disruptions in the supply chain or unsatisfactory performance, which could impact their business relationships and payments.

Next Steps

• Complete late-stage clinical testing of QRX003 in Netherton Syndrome.
• If successful, submit for marketing approval for QRX003 in the U.S., Europe, Japan, and other territories.
• Establish own sales infrastructure in the U.S., Europe, and Japan for QRX003.
• Work with distribution partners to commercialize QRX003 in Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, and Singapore.
• Continue development of QRX003 for Peeling Skin Syndrome and related rare, genetic skin diseases.
• Expand the Peeling Skin Syndrome study to include up to an additional five pediatric subjects.
• Commence clinical testing of one or more selected formulations of topical rapamycin (QRX009).
• Submit a pre-IND meeting request to the FDA for QRX009 before the end of Q2 of 2026.
• Initiate a pharmacokinetic study for QRX009 in healthy volunteers in Q2 of 2026.
• Manufacture clinical trial and stability batches for QRX009 with a view to commencing clinical testing in the second half of 2026.
• Pursue business development activities by seeking partnering, licensing, merger, and acquisition opportunities to expand the pipeline.
• Schedule a meeting with QUT to discuss the future direction of the Scleroderma research program (QRX008).
• Obtain further funding through public or private offerings of capital stock, debt financing, warrant exercises, collaboration, strategic, and/or licensing arrangements, or grants.
• The Series H Warrants will remain exercisable until five (5) years from the October 2025 Closing Date.
• The Series I Warrants may be exercised based on primary endpoint achievement in monotherapy and adjuvant pivotal trials of QRX003 for NS.
• The Series J Warrants may be exercised based on FDA approval (accelerated or traditional) of QRX003 for NS.
• The Series K Warrants may be exercised based on the sale of a Priority Review Voucher (PRV).
• The 2025 Equity Incentive Plan will have an automatic annual increase in authorized shares on January 1st of each calendar year beginning in 2026 and ending on January 1, 2035.

Key Dates

Recommendation

Quoin Pharmaceuticals presents a high-risk, high-reward profile. The significant clinical progress and multiple regulatory designations for QRX003 in Netherton Syndrome are strong positive catalysts, indicating potential for market approval and future revenue. However, the company's substantial accumulated deficit, increasing net losses, and explicit 'going concern' warning signal severe financial instability and a critical need for further capital. The restrictive covenants from the October 2025 private placement could complicate future financing efforts. While the long-term potential exists if QRX003 succeeds, the immediate financial risks are considerable. A 'hold' recommendation reflects the balance between promising clinical developments and acute financial challenges, advising investors to monitor upcoming clinical milestones and financing activities closely before making further investment decisions.

Keywords

Netherton Syndrome, QRX003, Rare Disease, Orphan Disease, Pharmaceutical, Clinical Trials, FDA, SEC, Nasdaq, Biopharmaceutical, Drug Development, Peeling Skin Syndrome, Scleroderma, Rapamycin, Sirolimus, QNRX, 10-K, Financials, Going Concern, Equity Raise, Warrants, Intellectual Property, Corporate Governance